Tempramed receives validation of payer ROI model

Executive Summary

• Tempramed Technologies received independent validation of its payer Return-on-Investment (ROI) model from the Validation Institute, confirming that its products (Vivi Cap and Vivi Epi) generate significant cost savings for health care payers.
• The validation establishes a credible, reimbursement-driven growth pathway, allowing Tempramed to advance pilot programs with U.S. health care payers to secure coverage for its temperature-sensitive medication storage devices.
• The validated model is effective through January 2027 and includes a formal credibility guarantee, positioning the company to demonstrate real-world savings and accelerate reimbursement decisions.

Key Details

• Validation Authority: The Validation Institute, described as a leading authority in health care economic credibility in the United States.
• Validated Products: Vivi Cap and Vivi Epi, used for temperature-sensitive injectable medications including insulin, GLP-1 therapies, biologics, and epinephrine.
• Savings Drivers: The model confirms savings driven by reduced medication waste, fewer adverse clinical events, improved patient adherence, and lower anxiety-related health care utilization.
• Validation Scope: The Validation Institute reviewed Tempramed's savings methodology, assumptions, and calculations, confirming they meet or exceed industry standards for health care economic analysis.
• Validity Period: The validation and formal credibility guarantee are effective through January 2027.
• Next Steps: Tempramed is advancing discussions with U.S. health care payers, introduced by the Validation Institute through its purchaser network, to initiate pilot programs.
• Pilot Objectives: Payers will confirm real-world savings outcomes to accelerate coverage and reimbursement decisions for Vivi Cap and Vivi Epi.
• Target Markets: Pilot programs aim to serve as a catalyst for adoption across national and regional health plans, employer-sponsored plans, and value-based integrated care organizations.
• Strategic Impact: CEO Ron Nagar described the validation as a "major inflection point" that provides independent, third-party confirmation of the economic compelling nature of the device for payers, changing the scale of the opportunity.
• Partnership Potential: General Manager Daniel Salomon noted that success in demonstrating cost reductions could strengthen partnerships with pharmaceutical manufacturers focused on patient support and adherence.

Notable Quotes

• Ron Nagar, CEO: "This validation represents a major inflection point for Tempramed and is a meaningful step in the right direction in our reimbursement strategy to begin receiving payer coverage from major U.S. payers and others for our products... For the first time, we have independent, third party confirmation that Vivi Cap is not only meaningful for patients -- but also economically compelling for payers."
• Ron Nagar, CEO: "Our discussions with payers are now grounded in validated economics, not assumptions... Successful pilot programs can unlock recurring, high-volume demand and position Tempramed as a standard-of-care solution across multiple chronic disease categories."
• Al Lewis, Founder and Validator-in-Chief, Validation Institute: "Tempramed's Vivi Cap ROI model meets our standards for credible, transparent savings analysis. The economics demonstrate that payers covering this device can achieve rapid return on investment while improving outcomes for patients using temperature-sensitive medications."